Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck To Close Plant In South Korea As Part Of Global Supply Strategy

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Merck will close down its plant in South Korea, the U.S.-based drug maker said Nov. 3

You may also be interested in...



Banyu to Close Tsukuba Lab as Part of Merck’s Global Research Revamp

TOKYO - Merck subsidiary Banyu Pharmaceutical, said Oct. 23 it would close its research laboratory in Tsukuba City, northeast of Tokyo, by the end of 2009, leaving only a fraction of foreign drug makers with basic research activities in Japan

Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)

[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel